Minireviews
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 14, 2017; 23(2): 197-203
Published online Jan 14, 2017. doi: 10.3748/wjg.v23.i2.197
Biosimilars in inflammatory bowel disease: A review of post-marketing experience
Simona Deiana, Tommaso Gabbani, Vito Annese
Simona Deiana, Tommaso Gabbani, Vito Annese, Division of Gastroenterology, AOU Careggi University Hospital, 50139 Firenze, Italy
Author contributions: Gabbani T performed literature research, wrote the first draft and reviewed the article; Deiana S collaborated to literature search and reviewed the article; Annese V designed and coordinated the review, and revised the final draft the manuscript.
Conflict-of-interest statement: No potential conflicts of interest relevant to this article were reported.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Vito Annese, MD, Emergency Department, Division of Gastroenterology, AOU Careggi University Hospital, Largo Brambilla 3, 50139 Firenze, Italy. annesev@aou-careggi.toscana.it
Telephone: +39-55-7946035
Received: August 30, 2016
Peer-review started: August 31, 2016
First decision: September 21, 2016
Revised: October 1, 2016
Accepted: December 21, 2016
Article in press: December 21, 2016
Published online: January 14, 2017
Processing time: 134 Days and 20.3 Hours
Abstract

Biologic compounds are obtained from living organisms or cell cultures by means of biotechnology methods. A similar biologic drug, commonly called biosimilar, is a product copied by a native approved biologic drug whose license has expired. Biosimilar drugs usually are marketed at a lower price and provide important financial savings for public healthcare systems. Some differences between biosimilars and original biologic drugs might exist but they are acceptable if they fall within defined “boundaries of tolerance”: differences in some features between the two molecules are considered important only if clinical relevant. Considering that the efficacy of the innovator biologic drug has already been established, the clinical studies required for approval of a biosimilar could be reduced compared with those required for the approval of the originator. In this review, real life data available in inflammatory bowel disease patients treated with biosimilars are reported, documenting in general satisfactory outcomes, sustained efficacy and no sign of increased immunogenicity, although, further controlled data are awaited.

Keywords: Adalimumab biosimilar; CTP-13; ZRC-3197; Infliximab biosimilars; Biologic drugs

Core tip: Some differences between biosimilars and original biologic drugs exist but they are acceptable if they fall within defined “boundaries of tolerance”: variations in some features of the two molecules are considered important only if clinical relevant. Several real-life clinical data are already available in inflammatory bowel disease patients treated with biosimilars with satisfactory outcomes, but further controlled trials are awaited.